Overview

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, multicenter, phase Ib study to evaluate the safety and efficacy of ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors (chemotherapy) as first-line therapy in Participants with extensive stage small cell lung cancer.
Phase:
PHASE1
Details
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd